1. Home
  2. KF vs CNTN Comparison

KF vs CNTN Comparison

Compare KF & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Korea Fund Inc. (The) New

KF

Korea Fund Inc. (The) New

HOLD

Current Price

$43.72

Market Cap

197.9M

Sector

Finance

ML Signal

HOLD

CNTN

Canton Strategic Holdings Inc. Common Stock

N/A

Current Price

$3.23

Market Cap

184.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KF
CNTN
Founded
1984
2017
Country
United States
United States
Employees
N/A
3
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
197.9M
184.2M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
KF
CNTN
Price
$43.72
$3.23
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
28.6K
462.2K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.15
$3.07
52 Week High
$58.59
$5.27

Technical Indicators

Market Signals
Indicator
KF
CNTN
Relative Strength Index (RSI) 40.44 29.81
Support Level $31.38 $3.15
Resistance Level $49.38 $3.51
Average True Range (ATR) 1.89 0.30
MACD -0.68 -0.05
Stochastic Oscillator 21.19 7.19

Price Performance

Historical Comparison
KF
CNTN

About KF Korea Fund Inc. (The) New

Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and Others.

About CNTN Canton Strategic Holdings Inc. Common Stock

Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.

Share on Social Networks: